Valirx (VAL)

 

Latest News

Holding(s) in Company

RNS Number: 8629N ValiRx PLC 11 May 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Valirx plc 1b. Please indicate ...

Result of AGM

RNS Number: 3756N ValiRx PLC 08 May 2018 ValiRx Plc ("ValiRx" or the "Company") Result of Annual General Meeting London, UK ., 08 May 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , announces that at its Annual General Meeting ("AGM") held earlier today, resolutions 1-5 were passed and resolutions 6 and 7 were withdrawn. *** E...

Second Price Monitoring Extn

RNS Number: 2351N ValiRx PLC 04 May 2018 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined percentage ab...

Price Monitoring Extension

RNS Number: 2342N ValiRx PLC 04 May 2018 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the execution occurs. A ...

All News

DateHeadlineSource
11-05-18Holding(s) in CompanyRNS
08-05-18Result of AGMRNS
04-05-18Second Price Monitoring ExtnRNS
04-05-18Price Monitoring ExtensionRNS
04-05-18Placing and grant of warrantsRNS
26-04-18Second Price Monitoring ExtnRNS
26-04-18Price Monitoring ExtensionRNS
25-04-18Second Price Monitoring ExtnRNS
25-04-18Price Monitoring ExtensionRNS
25-04-18ValiRx cancer treatment granted European patentStockMarketWire
25-04-18EU Patent Grant for Therapeutic Compound, VAL201RNS
20-04-18ValiRx (VAL): 2017: a pivotal yearRNS
19-04-18FTSE gains momentum on upbeat corporate newsStockMarketWire
19-04-18GENEICE & VAL101 UpdateRNS
19-04-18ValiRx - Positive results from VAL101BRR Media
12-04-18Notice of AGMRNS
10-04-18ValiRx losses narrow on lower R&D costsStockMarketWire
10-04-18Final ResultsRNS
10-04-18ValiRx - Final ResultsBRR Media
20-03-18ValiRx granted US patent for therapeutic anti-cancer compoundStockMarketWire
20-03-18US Patent Grant for Therapeutic Compound, VAL201RNS
19-03-18Holding(s) in CompanyRNS
16-03-18Appointment of BrokerRNS
02-03-18Statement re brokerRNS
09-02-18Issue of options and directors dealingsRNS
06-02-18ValiRx - Company UpdateBRR Media
02-02-18Holding(s) in CompanyRNS
25-01-18Holding(s) in CompanyRNS
23-01-18Holding(s) in CompanyRNS
23-01-18Valirx to present on 13 February 2018 at the Shares and AJ Bell Spotlight Evening in LondonStockMarketWire
16-01-18ValiRx welcomes positive clinical resultsStockMarketWire
16-01-18ValiSeek Clinical Update (VAL401)RNS
16-01-18ValiRx - ValiSeek Clinical Update, VAL401BRR Media
11-01-18ValiRx gets patent approval in the USStockMarketWire
11-01-18US Patent Notice of Allowance for Compound VAL201RNS
11-01-18ValiRx - US Patent Grant for VAL201BRR Media
04-01-18Holding(s) in CompanyRNS
03-01-18Exercise of Warrants and Issue of EquityRNS
27-12-17Final Loan Note Conversion and Issue of EquityRNS
22-12-17Issue of EquityRNS

RSS feeds

  • Editorial news feed for LSE:VAL Editorial
  • Regulatory news feed for LSE:VAL Regulatory